CureVac N.V. is a German biopharmaceutical company that develops therapies based on messenger RNA (mRNA). Headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac has approximately 375 employees since May 2018. At the beginning of the COVID-19 pandemic, CureVac was considered a beacon of hope for the development of a German vaccine. The federal government invested 300 million euros in the company. First, the CureVac vaccine was delayed due to minor problems, while the previously unknown BioNTech backed by Pfizer developed the very effective BNT162b2. In mid-2021, however, it became clear that the CureVac-vaccine was only 47 percent effective and is far away from approval. More information...
According to PR-model, curevac.com is ranked 296,614th in multilingual Wikipedia, in particular this website is ranked 39,243rd in German Wikipedia.
The website is placed before confeitariacolombo.com.br and after scanno.org in the BestRef global ranking of the most important sources of Wikipedia.
